Improvement in cutaneous disease with menin inhibitor monotherapy in KMT2A rearranged AML

Documenti analoghi

• Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI‐503 against MLL::AF9‐driven acute myeloid leukaemia
  di: Wenqi Zhu, et al.
  Pubblicazione: (2024)
• Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high‐risk KMT2A ‐rearranged acute myeloid leukaemia
  di: Arundhati Chavan, et al.
  Pubblicazione: (2025)
• A CD10‐negative adult B‐lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature
  di: Huan‐You Wang, et al.
  Pubblicazione: (2024)
• Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10 AML with extensive extramedullary infiltration: A case report
  di: Rong Wang, et al.
  Pubblicazione: (2024)
• Correction to ‘Personalized therapy guided by single‐cell transcriptomic analysis in relapsed and refractory KMT2A::MLLT10 AML with extensive extramedullary infiltration: A case report’
  Pubblicazione: (2025)